Author: evathera

FDA approves Investigational New Drug (IND) that enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET) 

 New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors

Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting